Skip to main content
. Author manuscript; available in PMC: 2018 Feb 5.
Published in final edited form as: Eur J Pharm Sci. 2015 Oct 30;82:64–78. doi: 10.1016/j.ejps.2015.10.024

Fig. 6.

Fig. 6

Predictive check for PAPI study data on the impact of CES1 polymorphism on clopidogrel active metabolite (CLOP-AM) PK (A) as well as platelet reactivity (expressed as maximal platelet aggregation (MPA)) on Day 0 at baseline (B) and on Day 7 after clopidogrel treatment (C). Each individual plot presents individual observed data (circles) and boxplots for model predictions. TC: CES1 G143E mutation carriers; CC: CES1 wild-type subjects.